CTLA4 and melanoma: However, high-CD44-expression patients exhibited an extended PFS compared with low-CD44-expression patients in Gide2019_PD1+CTLA4-Melanoma and Prat2017_PD1-NSCLC-HNSC-Melanoma cohorts (Figure 8C).